RIC-Mel, a network of reference

The RIC-Mel network have an expertise recognised by the industry to develop:

- Clinical trials in the field of melanoma,
- Clinical and translational research in this pathology.

Our partners

- The Cancerology Group (GCC) of the French Society of Dermatology (SFD). Coordinated by Pr M.T. Leccia (Albert Michallon Hospital, Grenoble).
- MELBASE Coordinated by Pr C. Lebbé (Saint Louis Hospital, Paris) and by Pr B. Dréno (Nantes Hospital). MELBASE is a clinico-biologico-radiological database only for patients with metastatic melanoma stage IV and unresectable stage III.
- The Ille de France Melanoma Network Coordinated by Dr L. Larue (Curie Institute, Paris). This network includes the consortium Melan Cohort (clinical and biological follow up of a group of patients) coordinated by Pr P. Saiag (Ambroise Paré Hospital, Boulogne Billancourt) and by Pr V. Descamps (Bichat Hospital, Paris).
- The Far West Biotherapies and Researches in Dermatology Network (BIORDERM). Coordinated by Pr B. Dréno (Nantes Hospital). This network is formed by hospital clinical units and primary research units in Nantes, Angers, Brest, Caen, Le Mans, Rennes, Poitiers, Tours, La Roche sur Yon et La Rochelle.
- The West Melanoma Network Coordinated by Pr B. Dréno (Nantes hospital). It is a city-hospital network.
- The patients association AMESA

Our supports

- The National Cancer Institute (INCa).
- The National Centre for Healthcare Products Trial Management (CeNGEPS).
- AMGEN, BMS, GSK, MSD and Roche.

Who are we?

The RIC-Mel network brings together clinicians researchers working in clinical and translational research for melanoma and carrying out all the patients inclusions in the clinical trials.

The network consists of 49 centres spread across the national territory:

- 43 dermatology centres (CH, CHU, CHR, CH, HIA)
- 6 Cancer centres

Since the database was launched in 2012, 21,838 patients were included (09 April 2018)

Our objectives

- To federate the clinical cancerology and dermatology sites and the existing networks in melanoma around a common database,
- To be a preferred interlocutor for the industry,
- To ensure close interaction between all the hospital disciplines involved in melanoma evaluation,
- To ensure the functioning of a national clinical database,
- To ensure interactions between clinical and translational research as well as to support basic research.
The file active of patients with melanoma from each participating centre is available in the RIC-Mel database.

The RIC-Mel database has been approved by French health authorities, both ethically and for confidentiality of data (CNIL and CCTIRS). The database is available on the internet at any given moment thanks a secure connection. All data are treated confidentially.

Collected data describes key information needed for any epidemiological, translational or clinical research project:

### Part I - Mandatory
- Primary tumour
  - (date of surgery, breslow, ulceration, mitotic index, regression, histological type)
- Sentinel lymph node surgery and lymph node removal
  - (date, result, number of invaded lymph node, extracapsular extension)
- AJCC stage
- Mutation status
- Melanoma antigens
- Treatments
  - (type, name, dates, curative or adjuvant)
- Death

### Part II - Optional
- Family history
  - (genetic investigation)
- Metastases
  - (type, date of diagnostic, presence)
- HLA A and B type
- Biological samples
- Curative and experimental treatments
  - (dose, response, grade 3 and 4 side effects)
- Grade 3 and 4 side effects
  - (type, name, grade, action on treatment, outcome)

The RIC-Mel database is linked to the clinico-biologico-radiological database MELBASE, for patients with melanoma stage IV and unresectable stage III (Saint Louis Hospital, Paris).

### OUR DATABASE

### THE RIC-MEL NETWORK ENSURE TO YOU

- The rapid realization of clinical trials as well as the smooth progress of the ongoing clinical trials,
- A national recruitment with an international legibility,
- The development of your products (as some members of the RIC-Mel network are also early phase centres (CLIP2)),
- A permanently updated mapping of melanoma followed up in France thanks to our database.

### OUR GOVERNANCE

- **Steering Committee**
  - Strategic and operational decisions, implementation of the Quality management
- **Scientific council**
  - Assessment mission and setting of the conditions governing data access
- **Coordinators**
  - Pr Brigitte DRENO – Nantes Hospital
  - Pr Céleste LEBBE – Saint Louis Hospital, AP-HP
  - Management of the activity of centres and database, financial monitoring
- **Management mission**
  - Project manager of the RIC-Mel network
  - Quality unit of the Investigation Department
  - Review of the Quality management system
- **Support process**
  - Management of participants
  - Management of identifiers
  - Management of internal resources
  - Management of the follow-up
- **Operational**
  - Project manager of the RIC-Mel network
  - Quality unit of the Investigation Department
  - Review of the Quality management system

### OUR QUALITY MANAGEMENT SYSTEM

- **Steering process**
  - Strategy & Management
  - Security & quality management
  - Finances
  - Communication
- **Execution process**
  - Preparation of the cohort
  - Data collection
  - Quality control
  - Referencing
  - Valorisation of data

- **Support process**
  - Management of participants
  - Management of identifiers
  - Management of internal resources
  - Management of the follow-up